Efect of HER2‑low status on brain metastasis‑free survival and survival after brain metastasis in patients with breast cancer
-
Tuğba Önder [1] ; Cengiz Karaçin [1]
-
[1] Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Health Sciences University, Ankara, Türkiye
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 3, 2025, págs. 960-973
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Aims and objectives The discovery of novel human epidermal growth factor receptor 2 (HER2)-directed antibody‒drug conjugates has accelerated the identifcation of the HER2-low subtype. However, the biological signifcance of low HER2 expression in breast cancer brain metastasis (BCBM) is unclear.
Methods Patients with HER2-negative BC and brain metastasis were retrospectively screened between February 2012 and November 2023. Brain metastasis-free survival (BMFS) and survival after brain metastasis (SABM) were analyzed according to HER2 expression.
Results A total of 201 female patients, 84 of whom were HER2-low and 117 of whom were HER2-zero, were evaluated. The median BMFS in the entire cohort was 35.6 months (95% CI 29.8–41.4). Although HER2-low patients had numerically longer median BMFS than HER2-zero patients (43.7 m vs. 30.1 m, p=0.025), multivariate analysis revealed that the diference was not signifcant (p=0.167). BMFS between the HER2-low and HER2-zero groups was similar in the hormone receptor (HR)-positive (52.8 m vs. 47.6 m, p=0.276) and HR-negative (15.3 m vs. 19.7 m, p=0.930) cohorts. The median SABM in the entire cohort was 6.0 months (95% CI 3.8–8.1). HER2-low and HER2-zero patients had similar median SAMB (5.4 m vs. 6.1 m, p=0.816). The SABM between the HER2-low and HER2-zero groups was similar in the HR-positive (6.3 m vs. 8.7 m, p=0.375) and HR-negative (3.3 m vs. 4.2 m, p=0.783) cohorts.
Conclusions Low HER2 expression does not afect BMFS or SAMB in brain metastatic breast cancer patients in this realworld population.
